KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests: 2014-2018

Historic Income from Non-Controlling Interests for CRISPR Therapeutics AG (CRSP) over the last 5 years, with Dec 2018 value amounting to $52.5 million.

  • CRISPR Therapeutics AG's Income from Non-Controlling Interests rose 13.60% to $14.2 million in Q1 2019 from the same period last year, while for Mar 2019 it was $54.4 million, marking a year-over-year increase of 25.93%. This contributed to the annual value of $52.5 million for FY2018, which is 45.03% up from last year.
  • CRISPR Therapeutics AG's Income from Non-Controlling Interests amounted to $52.5 million in FY2018, which was up 45.03% from $36.2 million recorded in FY2017.
  • In the past 5 years, CRISPR Therapeutics AG's Income from Non-Controlling Interests ranged from a high of $52.5 million in FY2018 and a low of -$536,000 during FY2014.
  • In the last 3 years, CRISPR Therapeutics AG's Income from Non-Controlling Interests had a median value of $36.2 million in 2017 and averaged $29.6 million.
  • Data for CRISPR Therapeutics AG's Income from Non-Controlling Interests shows a peak YoY soared of 144,900.00% (in 2017) over the last 5 years.
  • Over the past 5 years, CRISPR Therapeutics AG's Income from Non-Controlling Interests (Yearly) stood at -$536,000 in 2014, then surged by 39.37% to -$325,000 in 2015, then spiked by 92.31% to -$25,000 in 2016, then spiked by 144,900.00% to $36.2 million in 2017, then skyrocketed by 45.03% to $52.5 million in 2018.